LB Latigo Biotherapeutics, Inc. Stock: price and directors' dealings · United States · SEC (Form 4)Track the Latigo Biotherapeutics, Inc. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the authority of SEC (Form 4). The latest transaction was filed on 12 August 2026 (C). Among the most active insiders: Foresite Capital Management V, LLC. The full history is openly available.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 12 August 2026
All Executives34 Thresholds0 Prospectus0 Other0
Declarations 34 total
● 10% Owner · Executives · 10 Aug 2026
4,975,543 shares Common Stock SEC:0001231919-26-000869:0
● 10% Owner · Executives · 10 Aug 2026
2,350,419 shares Common Stock SEC:0001231919-26-000869:1
● 10% Owner · Executives · 10 Aug 2026
494,800 shares Common Stock SEC:0001193125-26-345826:0
● 10% Owner · Executives · 10 Aug 2026
177,978 shares Common Stock SEC:0001193125-26-345826:1
● 10% Owner · Executives · 10 Aug 2026
938,979 shares Common Stock SEC:0001104659-26-093633:0
● 10% Owner · Executives · 10 Aug 2026
3,547,842 shares Common Stock SEC:0001104659-26-093633:1
● 10% Owner · Executives · 10 Aug 2026
1,027,635 shares Common Stock SEC:0001104659-26-093633:2
● 10% Owner · Executives · 10 Aug 2026
3,464,072 shares Common Stock SEC:0001104659-26-093633:3
● 10% Owner · Executives · 10 Aug 2026
1,484,401 shares Common Stock SEC:0001104659-26-093633:4
● 10% Owner · Executives · 10 Aug 2026
165,519 shares Common Stock SEC:0001104659-26-093633:5
● 10% Owner · Executives · 10 Aug 2026
2,066,857 shares Common Stock SEC:0001104659-26-093633:6
● 10% Owner · Executives · 10 Aug 2026
3,117,664 shares 0Common Stock SEC:0001104659-26-093580:0
● 10% Owner · Executives · 10 Aug 2026
445,320 shares 0Common Stock SEC:0001104659-26-093580:1
● 10% Owner · Executives · 10 Aug 2026
742,201 shares 0Common Stock SEC:0001104659-26-093580:3
● 10% Owner · Executives · 10 Aug 2026
3,117,664 shares 0Common Stock SEC:0001104659-26-093580:6
● 10% Owner · Executives · 10 Aug 2026
296,880 shares 0Common Stock SEC:0001104659-26-093580:7
● Director · Executives · 10 Aug 2026
938,979 shares Common Stock SEC:0001184592-26-000005:0
● Director · Executives · 10 Aug 2026
195,776 shares Common Stock SEC:0001581754-26-000006:5
● Director · Executives · 10 Aug 2026
3,117,664 shares Common Stock SEC:0001581754-26-000006:6
● 10% Owner · Executives · 10 Aug 2026
1,125,823 shares 0Common Stock SEC:0001104659-26-093580:2
● 10% Owner · Executives · 10 Aug 2026
195,776 shares Common Stock SEC:0001104659-26-093580:5
● Director · Executives · 10 Aug 2026
3,547,842 shares Common Stock SEC:0001184592-26-000005:1
● Director · Executives · 10 Aug 2026
1,027,635 shares Common Stock SEC:0001184592-26-000005:2
● Director · Executives · 10 Aug 2026
3,464,072 shares Common Stock SEC:0001184592-26-000005:3
● Director · Executives · 10 Aug 2026
1,484,401 shares Common Stock SEC:0001184592-26-000005:4
25 of 34 declarations
Load more (9 remaining) About Latigo Biotherapeutics, Inc. Latigo Biotherapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for autoimmune diseases. It is listed on NASDAQ under the ticker symbol XNAS.